Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hamps BioBOM:544312 -2.17%12 Current Ratio is 1.46 as of Mar. 2026, which is at its 10-year median of 1.46. GuruFocus rates BOM:544312 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 682 Healthcare Providers & Services companies, Hamps Bio ranks better than 50.44% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Hamps Bio's current ratio for the quarter that ended in Mar. 2026 was 1.46.
Hamps Bio has a current ratio of 1.46. It generally indicates good short-term financial strength.
The historical rank and industry rank for Hamps Bio's Current Ratio or its related term are showing as below:
BOM:544312'
s Current Ratio Range Over the Past 10 Years
Min: 0.59 Med: 1.46 Max: 2.26
Current: 1.46
During the past 5 years, Hamps Bio's highest Current Ratio was 2.26. The lowest was 0.59. And the median was 1.46.
BOM:544312's Current Ratio is ranked better than 50.44% of 682
companies
in the Healthcare Providers & Services industry
Industry Median: 1.455
vs BOM:544312: 1.46
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Hamps Bio Current Ratio Related Terms
Hamps Bio Current Ratio Historical Data
* Premium members only.
The historical data trend for Hamps Bio's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Hamps Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hamps Bio Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hamps Bio's Current Ratio distribution charts can be found below:
* The bar in red indicates where Hamps Bio's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamps Bio (BOM:544312) has a Current Ratio of 1.46 as of Mar. 2026. This is near median its historical median of 1.46. Over the past decade, Hamps Bio's Current Ratio has ranged from 0.59 to 2.26. According to the industry distribution chart, Hamps Bio ranks #338 out of 682 companies in the Healthcare Providers & Services industry, placing it in the top 49.6%.
Is Hamps Bio's Current Ratio too high?
Hamps Bio's current Current Ratio of 1.46 is near median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 2.26. The Healthcare Providers & Services industry median Current Ratio is 1.46. Hamps Bio's value of 1.46 is 0.3% above this industry median. Based on the distribution chart, Hamps Bio ranks #338 out of 682 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Hamps Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Hamps Bio's Current Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Hamps Bio ranks #338 out of 682 companies for Current Ratio. This puts Hamps Bio in the upper half of its industry. The industry median Current Ratio is 1.46. Hamps Bio's value of 1.46 is 0.3% above this benchmark. Historically, Hamps Bio's own Current Ratio has ranged from 0.59 to 2.26 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 1.46, Hamps Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.46, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hamps Bio's current Current Ratio of 1.46 is 0.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamps Bio's current Current Ratio is 1.46, which is near median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamps Bio stock overvalued right now?
Hamps Bio (BOM:544312) has a current Current Ratio of 1.46. The current Current Ratio is 1.46, which is near median its 10-year median of 1.46 and 0.3% above the Healthcare Providers & Services industry median of 1.46. Hamps Bio's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Hamps Bio (BOM:544312), the current Current Ratio is 1.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hamps Bio Ltd is engaged in the ethical marketing and distribution of pharmaceutical formulation products. Its product include tablets, syrups, capsules, injectables, oil, gel and powder used as medicine and nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers. The company segment includes Manufacturing, trading and distribution of Pharmaceutical formulation products and Manufacturing of Freeze dried and frozen products like fruits, vegetables, herbs, flowers, etc. Key revenue is generated from Medicine Products.
12GF Score
Get the complete analysis for BOM:544312
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544312 has been successfully added to your 
